Surface Oncology, Inc. Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • March 30th, 2018 • Surface Oncology, Inc. • Biological products, (no disgnostic substances) • New York
Surface Oncology, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representatives (the “Representatives”) an aggregate of [•] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [•] additional shares (the “Optional Shares”) of common stock, par value $0.0001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Re: Contingent Employment Agreement Termination LetterSurface Oncology, Inc. • March 30th, 2018 • Biological products, (no disgnostic substances)
Reference is hereby made to that certain Employment Agreement (the “Agreement”) dated as of November 23, 2016, by and between Surface Oncology, Inc. (the “Company”), and you.
STOCK PURCHASE AGREEMENTStock Purchase Agreement • March 30th, 2018 • Surface Oncology, Inc. • Biological products, (no disgnostic substances)
THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of March 29, 2018 (the “Effective Date”), by and between Surface Oncology, Inc., a Delaware corporation (the “Company”) and Novartis Institutes for Biomedical Research, Inc. (“Purchaser”).
